Overview

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

Status:
RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
Phase:
PHASE2
Details
Lead Sponsor:
Sunhawk Vision Biotech, Inc.
Treatments:
Atropine